PAR2

PAR2 Informations sur la molécule

Nom anglais	Protease-activated receptor-2	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	3	Alias de la cible	Receptor， PAR-2，F2RL1，Thrombin receptor-like 1，G-protein coupled receptor 11，F2R Like Trypsin Receptor 1，PAR2，GPR11，Protease-Activated Receptor 2，Coagulation Factor II (Thrombin) Receptor-Like 1，Proteinase-Activated Receptor-2，Proteinase-activated receptor 2，Coagulation factor II receptor-like 1
Phase de R&D la plus avancée	Phase 2 Clinical

Nom anglais	Protease-activated receptor-2
Alias de la cible	Receptor， PAR-2，F2RL1，Thrombin receptor-like 1，G-protein coupled receptor 11，F2R Like Trypsin Receptor 1，PAR2，GPR11，Protease-Activated Receptor 2，Coagulation Factor II (Thrombin) Receptor-Like 1，Proteinase-Activated Receptor-2，Proteinase-activated receptor 2，Coagulation factor II receptor-like 1
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	3
Phase de R&D la plus avancée	Phase 2 Clinical

PAR2 Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
- (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
PA2-H52P7	Human	HEK293	Human PAR2 Full Length Protein (VLP)				Ajouter au panier

Quantité totale1

PAR2Contexte de la molécule

This gene encodes a member of the G-protein coupled receptor 1 family of proteins. The encoded cell surface receptor is activated through proteolytic cleavage of its extracellular amino terminus, resulting in a new amino terminus that acts as a tethered ligand that binds to an extracellular loop domain. Activation of the receptor has been shown to stimulate vascular smooth muscle relaxation, dilate blood vessels, increase blood flow, and lower blood pressure. This protein is also important in the inflammatory response, as well as innate and adaptive immunity. [provided by RefSeq, Jun 2016]

PAR2Alias de la molécule

PAR2

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
MEDI-0618	MEDI-0618; MEDI0618; ABBV-2002; ABBV2002	Phase 2 Clinical	Astrazeneca Plc	Chronic Pain; Migraine Disorders	Details
TEV-56192	TEV-56192	Phase 1 Clinical	Teva Pharmaceutical Industries Ltd	Nervous System Diseases	Details
OA-235i	OA-235i	Phase 1 Clinical	Oasis Pharmaceuticals LLC	Metabolic Dysfunction-Associated Steatotic Liver Disease	Details